相关实验视频
Updated: Jun 23, 2025

10:28
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
9.7K
描述西班牙的型肝炎及其管理方面的差距
Sergio Rodríguez-Tajes1, Adriana Palom2, Álvaro Giráldez-Gallego3
1Hospital Clínic, Universitat de Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain.
概括
慢性肝炎D (CHD) 患者在诊断时通常有肝硬化. 持续的型肝炎病毒 (HDV) 病毒病加速肝病的进展,突出显示新疗法之前的管理挑战.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 临床医学 临床医学
背景情况:
- 慢性肝炎D (CHD) 是一种严重的肝病.
- 在西班牙,肝炎三角病毒 (HDV) 影响了大约5%的乙型肝炎病毒 (HBV) 患者.
- 在西班牙,新的抗病毒疗法,如布莱维尔提德 (BLV) 面临到2024年2月之前的退款延迟.
研究的目的:
- 为了描述西班牙HDV/HBV感染患者的临床概况.
- 在BLV批准之前,确定CHD患者的管理障碍.
主要方法:
- 在西班牙30个中心进行了一项多中心注册表研究.
- 收集了流行病学,临床和病毒学变量数据.
- 积极抗HDV血清的患者被积极监测.
主要成果:
- 确定了329名抗HDV患者;33%的患者在诊断时患有肝硬化.
- 持续的HDV病毒病与肝硬化发病率较高 (58%与25%相比) 有关.
- 在随访期间,10%的患者患有肝硬化,随着病毒病的进展. 发现了HDV-RNA量化中的障碍.
结论:
- 在诊断时,显著比例的CHD患者患有肝硬化.
- 持续的HDV病毒病是导致肝病快速进展的关键因素.
- 当地HDV-RNA测试的挑战给管理带来了障碍.
相关概念视频
Esophageal Varices-II: Clinical Features and Management
57
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
57
Pleural Effusion II: Symptoms and Management
165
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
165
Diseases of the Liver and Gallbladder
508
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
508
Gastritis III: Clinical Manifestations and Management
214
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
214
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
38
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
38
Chronic Pancreatitis II: Collaborative Care
84
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
84

